41 results match your criteria rvsv-zebov vaccination


'Learn from the lessons and don't forget them': identifying transferable lessons for COVID-19 from meningitis A, yellow fever and Ebola virus disease vaccination campaigns.

BMJ Glob Health 2021 Sep;6(9)

UK Public Health Rapid Support Team, London School of Hygiene & Tropical Medicine/Public Health England, London, UK.

Introduction: COVID-19 vaccines are now being distributed to low- and middle-income countries (LMICs), with global urgency surrounding national vaccination plans. LMICs have significant experience implementing vaccination campaigns to respond to epidemic threats but are often hindered by chronic health system challenges. We sought to identify transferable lessons for COVID-19 vaccination from the rollout of three vaccines that targeted adult groups in Africa and South America: MenAfriVac (meningitis A); 17D (yellow fever) and rVSV-ZEBOV (Ebola virus disease). Read More

View Article and Full-Text PDF
September 2021

Feasibility and safety of rVSV-ZEBOV vaccination of humanitarian health workers against Ebola virus disease: an observational study.

J Travel Med 2021 Jun 15. Epub 2021 Jun 15.

Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 6, Geneva 1205, Switzerland.

Background And Rationale: Geneva University Hospitals were granted a temporary authorization to administer the recombinant live vesicular stomatitis virus rVSV-ZEBOV (Ervebo®) vaccine to expatriate humanitarian frontline workers (FLWs) prior to mission deployment.

Objectives: Our aims were to assess the feasibility of FLW vaccination before deployment and to report adverse events (AEs).

Methods: FLWs received a single injection of rVSV-ZEBOV (>7. Read More

View Article and Full-Text PDF

Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine.

bioRxiv 2021 Jan 19. Epub 2021 Jan 19.

The ongoing pandemic of Coronavirus disease 2019 (COVID-19) continues to exert a significant burden on health care systems worldwide. With limited treatments available, vaccination remains an effective strategy to counter transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recent discussions concerning vaccination strategies have focused on identifying vaccine platforms, number of doses, route of administration, and time to reach peak immunity against SARS-CoV-2. Read More

View Article and Full-Text PDF
January 2021

Modelling the daily risk of Ebola in the presence and absence of a potential vaccine.

Infect Dis Model 2020 15;5:905-917. Epub 2020 Oct 15.

Department of Mathematics and Faculty of Medicine, The University of Ottawa, 150 Louis-Pasteur Pvt, Ottawa, ON, K1N6N5, Canada.

Ebola virus - one of the deadliest viral diseases, with a mortality rate around 90% - damages the immune system and organs, with symptoms including episodic fever, chills, malaise and myalgia. The Recombinant Vesicular Stomatitis Virus-based candidate vaccine (rVSV-ZEBOV) has demonstrated clinical efficacy against Ebola in ring-vaccination clinical trials. In order to evaluate the potential effect of this candidate vaccine, we developed risk equations for the daily risk of Ebola infection both currently and after vaccination. Read More

View Article and Full-Text PDF
October 2020

Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins.

Viruses 2020 08 20;12(9). Epub 2020 Aug 20.

Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany.

The last seven years have seen the greatest surge of Ebola virus disease (EVD) cases in equatorial Africa, including the 2013-2016 epidemic in West Africa and the recent epidemics in the Democratic Republic of Congo (DRC). The vaccine clinical trials that took place in West Africa and the DRC, as well as follow-up studies in collaboration with EVD survivor communities, have for the first time allowed researchers to compare immune memory induced by natural infection and vaccination. These comparisons may be relevant to evaluate the putative effectiveness of vaccines and candidate medical countermeasures such as convalescent plasma transfer. Read More

View Article and Full-Text PDF

Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment.

Nat Commun 2020 07 27;11(1):3736. Epub 2020 Jul 27.

Galveston National Laboratory, University of Texas Medical Branch, 301 University Blvd, Galveston, TX, 77555-0610, USA.

A replication-competent vesicular stomatitis virus vaccine expressing the Ebola virus (EBOV) glycoprotein (GP) (rVSV-ZEBOV) was successfully used during the 2013-16 EBOV epidemic. Additionally, chimeric and human monoclonal antibodies (mAb) against the EBOV GP have shown promise in animals and humans when administered therapeutically. Uncertainty exists regarding the efficacy of postexposure antibody treatments in the event of a known exposure of a recent rVSV-ZEBOV vaccinee. Read More

View Article and Full-Text PDF

Epitopes of Naturally Acquired and Vaccine-Induced Anti-Ebola Virus Glycoprotein Antibodies in Single Amino Acid Resolution.

Biotechnol J 2020 Sep 8;15(9):e2000069. Epub 2020 Jun 8.

Max Planck Institute of Colloids and Interfaces, Department of Biomolecular Systems, Potsdam, 14476, Germany.

The Ebola virus (EBOV) can cause severe infections in humans, leading to a fatal outcome in a high percentage of cases. Neutralizing antibodies against the EBOV surface glycoprotein (GP) can prevent infections, demonstrating a straightforward way for an efficient vaccination strategy. Meanwhile, many different anti-EBOV antibodies have been identified, whereas the exact binding epitopes are often unknown. Read More

View Article and Full-Text PDF
September 2020

Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination.

NPJ Vaccines 2020 14;5(1):32. Epub 2020 Apr 14.

1Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.

The rVSV-ZEBOV Ebolavirus vaccine confers protection within days after immunization, suggesting the contribution of innate immune responses. We report modulation of rVSV-ZEBOV vaccinee blood CD56 NK cell numbers, NKG2D or NKp30 surface receptor expression, Killer Immunoglobulin-like Receptor (KIR) cell percentages and NK-cell-related genes on day 1 post immunization. Inverse correlations existed between the concentration of several plasma cytokines and inhibitory KIR CD56 or cytokine-responsive CD56 NK cells. Read More

View Article and Full-Text PDF

Prior vaccination with recombinant Vesicular Stomatitis Virus - Zaire Ebolavirus vaccine is associated with improved survival among patients with Ebolavirus infection.

Vaccine 2020 03 21;38(14):3003-3007. Epub 2020 Feb 21.

Department of Pediatrics, University of Alberta, Edmonton, AB, Canada; Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada; School of Public Health, University of Alberta, Edmonton, AB, Canada; Distinguished Researcher, Stollery Science Lab, University of Alberta, Edmonton, AB, Canada; Women and Children's Research Institute, University of Alberta, Edmonton, AB, Canada. Electronic address:

The second largest Ebolavirus disease (EVD) outbreak ever recorded is currently ongoing in Eastern Democratic Republic of the Congo (DRC). This is the first outbreak for which the recombinant Vesicular Stomatitis Virus - Zaire Ebolavirus (rVSV-ZEBOV) candidate vaccine has been widely administered, using a ring vaccination strategy. We examined whether prior vaccination with rVSV-ZEBOV impacts viral load, organ impairment, and survival among patients with EVD admitted to Ebola Treatment Units (ETUs) in the DRC. Read More

View Article and Full-Text PDF

Serum-free production of rVSV-ZEBOV in Vero cells: Microcarrier bioreactor versus scale-X™ hydro fixed-bed.

J Biotechnol 2020 Feb 30;310:32-39. Epub 2020 Jan 30.

Department of Bioengineering, McGill University, Montreal, QC, Canada. Electronic address:

Ebola virus disease outbreaks have repeatedly occurred on the African continent over the last decades, with more serious outbreaks in recent years. Being highly transmissible and associated to high fatality rates, it constitutes a serious threat to public health. Vaccination, however, may allow for efficient control of its propagation. Read More

View Article and Full-Text PDF
February 2020

Being Pregnant during the Kivu Ebola Virus Outbreak in DR Congo: The rVSV-ZEBOV Vaccine and Its Accessibility by Mothers and Infants during Humanitarian Crises and in Conflict Areas.

Authors:
David A Schwartz

Vaccines (Basel) 2020 Jan 22;8(1). Epub 2020 Jan 22.

Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.

The Ebola virus disease (EVD) outbreak that began in Kivu province of the Democratic Republic of the Congo (DRC) in July 2018 is the second largest in history. It is also the largest and most deadly of the ten Ebola outbreaks to occur in DRC, the country where Ebola was first identified during the 1976 Yambuku outbreak. The Kivu region is one of the most challenging locations in which to organize humanitarian assistance. Read More

View Article and Full-Text PDF
January 2020

Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report.

Clin Infect Dis 2020 12;71(11):2872-2879

Medical Research Council-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom.

Background: In October 2015, 65 people came into direct contact with a healthcare worker presenting with a late reactivation of Ebola virus disease (EVD) in the United Kingdom. Vaccination was offered to 45 individuals with an initial assessment of high exposure risk.

Methods: Approval for rapid expanded access to the recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV) vaccine as an unlicensed emergency medicine was obtained from the relevant authorities. Read More

View Article and Full-Text PDF
December 2020

Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV.

Nat Med 2019 10 7;25(10):1589-1600. Epub 2019 Oct 7.

Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.

Recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV) is the most advanced Ebola virus vaccine candidate and is currently being used to combat the outbreak of Ebola virus disease (EVD) in the Democratic Republic of the Congo (DRC). Here we examine the humoral immune response in a subset of human volunteers enrolled in a phase 1 rVSV-ZEBOV vaccination trial by performing comprehensive single B cell and electron microscopy structure analyses. Four studied vaccinees show polyclonal, yet reproducible and convergent B cell responses with shared sequence characteristics. Read More

View Article and Full-Text PDF
October 2019

rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment.

Vaccine X 2019 Apr 29;1:100009. Epub 2019 Jan 29.

Independent Expert, United Kingdom.

The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the safety and characteristics of live, recombinant viral vector vaccines. A recent publication by the V3SWG described live, attenuated, recombinant vesicular stomatitis virus (rVSV) as a chimeric virus vaccine for HIV-1 (Clarke et al., 2016). Read More

View Article and Full-Text PDF

Recombinant subunit vaccines protect guinea pigs from lethal Ebola virus challenge.

Vaccine 2019 11 16;37(47):6942-6950. Epub 2019 Jul 16.

Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, United States. Electronic address:

Ebola virus (EBOV) is among the deadliest pathogens known to man causing infrequent outbreaks of hemorrhagic disease. In humans, the case fatality rates in the outbreaks can reach 90%. During the West African epidemic almost 30,000 people were infected and of these over 11,000 fatalities were reported. Read More

View Article and Full-Text PDF
November 2019

Ebola epidemic in war-torn Democratic Republic of Congo, 2018: Acceptability and patient satisfaction of the recombinant Vesicular Stomatitis Virus - Zaire Ebolavirus Vaccine.

Vaccine 2019 04 13;37(16):2174-2178. Epub 2019 Mar 13.

Department of Pediatrics, University of Alberta, Edmonton, Canada; Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Canada; School of Public Health, University of Alberta, Edmonton, Canada. Electronic address:

Background: The current Ebola outbreak in Eastern Democratic Republic of the Congo (DRC) is the second largest in history and the first in which the recombinant Vesicular Stomatitis Virus - Zaire Ebolavirus (rVSV-ZEBOV) vaccine has been used at scale. We assessed side-effects, satisfaction, and attitudes toward the new vaccine.

Methods: Cross-sectional survey questionnaire from a convenience sample of 90 vaccine recipients and 96 community controls in Eastern DRC. Read More

View Article and Full-Text PDF

Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?

Expert Rev Vaccines 2018 12 15;17(12):1105-1110. Epub 2018 Nov 15.

b Centre for Vaccinology , University Hospitals and University of Geneva , Geneva , Switzerland.

Introduction: The live-attenuated recombinant vesicular stomatitis virus vaccine expressing the glycoprotein (GP) of Zaire Ebola virus (rVSV-ZEBOV) has proven immunogenic in humans and effective in field studies. Yet long-term durability of vaccine responses is unknown.

Areas Covered: We survey the evidence available in the literature for the durability of human responses to rVSV-ZEBOV. Read More

View Article and Full-Text PDF
December 2018

Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea.

Vaccine 2019 11 25;37(48):7171-7177. Epub 2018 Sep 25.

Epicentre, 8 rue Saint Sabin, 75011 Paris, France. Electronic address:

Background: As part of the ring vaccination trial in Guinea, Front Line Workers were invited to participate in a sub-study to provide additional information on the immunogenicity and safety of rVSVΔG/ZEBOV-GP. Here we summarize the information on the safety follow-up.

Methods: An open-label, non-randomized, immunogenicity evaluation of one dose of rVSVΔG/ZEBOV-GP was conducted in Conakry, Guinea between March 2015 and July 2016. Read More

View Article and Full-Text PDF
November 2019

Rhabdoviruses as vaccine platforms for infectious disease and cancer.

Biotechnol Genet Eng Rev 2018 Apr 21;34(1):122-138. Epub 2018 May 21.

a Alberta Children's Hospital Research Institute , Calgary , Canada.

The family Rhabdoviridae (RV) comprises a large, genetically diverse collection of single-stranded, negative sense RNA viruses from the order Mononegavirales. Several RV members are being developed as live-attenuated vaccine vectors for the prevention or treatment of infectious disease and cancer. These include the prototype recombinant Vesicular Stomatitis Virus (rVSV) and the more recently developed recombinant Maraba Virus, both species within the genus Vesiculoviridae. Read More

View Article and Full-Text PDF

Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.

Lancet Infect Dis 2018 07 5;18(7):738-748. Epub 2018 Apr 5.

Centre for Vaccinology, University Hospitals of Geneva, Geneva, Switzerland. Electronic address:

Background: The recombinant vesicular stomatitis virus (rVSV) vaccine expressing the Zaire Ebola virus (ZEBOV) glycoprotein is efficacious in the weeks following single-dose injection, but duration of immunity is unknown. We aimed to assess antibody persistence at 1 and 2 years in volunteers who received single-dose rVSV-ZEBOV in three previous trials.

Methods: In this observational cohort study, we prospectively followed-up participants from the African and European phase 1 rVSV-ZEBOV trials, who were vaccinated once in 2014-15 with 300 000 (low dose) or 10-50 million (high dose) plaque-forming units (pfu) of rVSV-ZEBOV vaccine to assess ZEBOV glycoprotein (IgG) antibody persistence. Read More

View Article and Full-Text PDF

Ebola could be eradicated through voluntary vaccination.

R Soc Open Sci 2018 Jan 24;5(1):171591. Epub 2018 Jan 24.

Department of Mathematics and Statistics, University of North Carolina at Greensboro, Greensboro, NC 27402, USA.

Ebola virus disease (EVD) is a severe infection with an extremely high fatality rate spread through direct contact with body fluids. A promising Ebola vaccine (rVSV-ZEBOV) may soon become universally available. We constructed a game-theoretic model of Ebola incorporating individual decisions to vaccinate. Read More

View Article and Full-Text PDF
January 2018

The potential impact of a prophylactic vaccine for Ebola in Sierra Leone.

Math Biosci Eng 2018 04;15(2):337-359

Rhodes College, Department of Mathematics and Computer Science, 2000 N. Parkway, Memphis, TN 38112, United States email:

The 2014 outbreak of Ebola virus disease (EVD) in West Africa was multinational and of an unprecedented scale primarily affecting the countries of Guinea, Liberia, and Sierra Leone. One of the qualities that makes EVD of high public concern is its potential for extremely high mortality rates (up to 90%). A prophylactic vaccine for ebolavirus (rVSV-ZEBOV) has been developed, and clinical trials show near-perfect efficacy. Read More

View Article and Full-Text PDF

Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report.

Lancet Infect Dis 2017 12 9;17(12):1276-1284. Epub 2017 Oct 9.

Ebola Response, Ministry of Health, Conakry, Guinea.

Background: In March, 2016, a flare-up of Ebola virus disease was reported in Guinea, and in response ring vaccination with the unlicensed rVSV-ZEBOV vaccine was introduced under expanded access, the first time that an Ebola vaccine has been used in an outbreak setting outside a clinical trial. Here we describe the safety of rVSV-ZEBOV candidate vaccine and operational feasibility of ring vaccination as a reactive strategy in a resource-limited rural setting.

Methods: Approval for expanded access and compassionate use was rapidly sought and obtained from relevant authorities. Read More

View Article and Full-Text PDF
December 2017

Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV.

Cell Rep 2017 08;20(9):2251-2261

University Medical Center Hamburg-Eppendorf, 1(st) Department of Medicine, 20246 Hamburg, Germany; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, 20246 Hamburg, Germany. Electronic address:

Predicting vaccine efficacy remains a challenge. We used a systems vaccinology approach to identify early innate immune correlates of antibody induction in humans receiving the Ebola vaccine rVSV-ZEBOV. Blood samples from days 0, 1, 3, 7, and 14 were analyzed for changes in cytokine levels, innate immune cell subsets, and gene expression. Read More

View Article and Full-Text PDF

Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine.

Curr Opin Virol 2017 04 28;23:88-94. Epub 2017 Apr 28.

World Health Organization Collaborating Center for Vaccine Immunology, Departments of Pathology-Immunology, University of Geneva, 1211 Geneva, Switzerland. Electronic address:

The rVSV-ZEBOV vaccine is currently the only Ebola vaccine with demonstrated clinical efficacy in a ring-vaccination clinical trial. It has been shown to be reactogenic but immunogenic and safe in several Phase I clinical studies. However, its mechanisms of protection are unknown and available immunogenicity data are mostly limited to classical serological analysis; it is now of paramount importance to apply cutting-edge technologies, including transcriptomic and metabolomic analyses, and to perform integrative analyses with standard serology and clinical data to comprehensively profile the rVSV-ZEBOV immune signature. Read More

View Article and Full-Text PDF

An update on the 2014 Ebola outbreak in Western Africa.

Asian Pac J Trop Med 2017 Jan 27;10(1):6-10. Epub 2016 Dec 27.

Department of Clinical Medicine, Education Division, Trinity College Dublin, The University of Dublin, Dublin, Ireland; Department of Cardiology, The Adelaide and Meath Hospital Dublin, Incorporating the National Children Hospital, Tallaght, Dublin, 24, Ireland; Egom Clinical and Translational Research Services, Dartmouth, NS, Canada. Electronic address:

The recent Ebola outbreak in Western Africa was the most devastating outbreak witnessed in recent times. There have been remarkable local and international efforts to control the crisis. Ebola Virus Disease is the focus of immense research activity. Read More

View Article and Full-Text PDF
January 2017

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).

Lancet 2017 02 23;389(10068):505-518. Epub 2016 Dec 23.

WHO, Geneva, Switzerland.

Background: rVSV-ZEBOV is a recombinant, replication competent vesicular stomatitis virus-based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus. We tested the effect of rVSV-ZEBOV in preventing Ebola virus disease in contacts and contacts of contacts of recently confirmed cases in Guinea, west Africa.

Methods: We did an open-label, cluster-randomised ring vaccination trial (Ebola ça Suffit!) in the communities of Conakry and eight surrounding prefectures in the Basse-Guinée region of Guinea, and in Tomkolili and Bombali in Sierra Leone. Read More

View Article and Full-Text PDF
February 2017

Containing Ebola at the Source with Ring Vaccination.

PLoS Negl Trop Dis 2016 Nov 2;10(11):e0005093. Epub 2016 Nov 2.

Laboratory for the Modeling of Biological and Socio-technical Systems, Northeastern University, Boston, Massachusetts, United States of America.

Interim results from the Guinea Ebola ring vaccination trial suggest high efficacy of the rVSV-ZEBOV vaccine. These findings open the door to the use of ring vaccination strategies in which the contacts and contacts of contacts of each index case are promptly vaccinated to contain future Ebola virus disease outbreaks. To provide a numerical estimate of the effectiveness of ring vaccination strategies we introduce a spatially explicit agent-based model to simulate Ebola outbreaks in the Pujehun district, Sierra Leone, structurally similar to previous modelling approaches. Read More

View Article and Full-Text PDF
November 2016

Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.

J Infect Dis 2016 10 5;214(suppl 3):S360-S366. Epub 2016 Aug 5.

Laboratory of Virology.

The Ebola virus (EBOV) epidemic in West Africa increased the focus on vaccine development against this hemorrhagic fever-causing pathogen, and as a consequence human clinical trials for a few selected platforms were accelerated. One of these vaccines is vesicular stomatitis virus (VSV)-EBOV, also known as rVSV-ZEBOV, a fast-acting vaccine against EBOV and so far the only vaccine with reported efficacy against EBOV infections in humans in phase III clinical trials. In this study, we analyzed the potential of VSV-EBOV for postexposure treatment of rhesus macaques infected with EBOV-Makona. Read More

View Article and Full-Text PDF
October 2016